Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer ; volume:10 ; number:4 ; day:16 ; month:7 ; year:2008 ; pages:1-8 ; date:8.2008
Breast cancer research ; 10, Heft 4 (16.7.2008), 1-8, 8.2008
- Creator
-
Cancello, Giuseppe
- Contributor
-
Montagna, Emilia
D'Agostino, Diego
Giuliano, Mario
Giordano, Antonio
Di Lorenzo, Giuseppe
Plaitano, Monica
De Placido, Sabino
De Laurentiis, Michele
SpringerLink (Online service)
- DOI
-
10.1186/bcr2119
- URN
-
urn:nbn:de:1111-201603241431
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cancello, Giuseppe
- Montagna, Emilia
- D'Agostino, Diego
- Giuliano, Mario
- Giordano, Antonio
- Di Lorenzo, Giuseppe
- Plaitano, Monica
- De Placido, Sabino
- De Laurentiis, Michele
- SpringerLink (Online service)
Other Objects (12)
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
Long-Term Non-progression in Metastatic Breast Cancer Beyond 5 Years: Case Series and Review
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
Correlation between NK function and response to trastuzumab in metastatic breast cancer patients
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Continuing Violation
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
Continuing education as value creation. Towards a new orientation beyond market logic
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
Long-Term Non-progression in Metastatic Breast Cancer Beyond 5 Years: Case Series and Review
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
Correlation between NK function and response to trastuzumab in metastatic breast cancer patients
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Continuing Violation
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
Continuing education as value creation. Towards a new orientation beyond market logic
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
Long-Term Non-progression in Metastatic Breast Cancer Beyond 5 Years: Case Series and Review
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
Correlation between NK function and response to trastuzumab in metastatic breast cancer patients
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Continuing Violation
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer